Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Stamford, Connecticut • Lake City, Florida + 20 more
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more
Completed Phase 2 Interventional Results available

Comparison of Rimegepant and Placebo for Pain in IBS

NCT06221111
Conditions
Irritable Bowel Syndrome
Interventions
Rimegepant 75 MG [Nurtec]
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Migraine
Interventions
Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
30
States / cities
Tempe, Arizona • Colton, California • Los Angeles, California + 27 more
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Conditions
Pain
Interventions
aspirin and ketamine, Nurtec (Rimegepant)
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Migraine
Interventions
Rimegepant, Not taking Rimegepant
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older · Female only
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Completed Phase 2 Interventional Results available

Rimegepant in Moderate Plaque-type Psoriasis

NCT04629950
Conditions
Psoriasis
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Conditions
Migraine
Interventions
BMS-927711 (CGRP Antagonist)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Glendale, California • Long Beach, California • Orlando, Florida + 1 more
Conditions
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions
rimegepant 75 mg ODT, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
33
States / cities
La Mesa, California • Panorama City, California • Roseville, California + 24 more
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more